seekingalpha.com
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc.MRVINASDAQ
Loading
Latest News
zacks.com
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.06 per share a year ago.
businesswire.com
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates. Key Financial Results: Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million; Annual revenue of $185.7 million, Net loss of.
defenseworld.net
Maravai LifeSciences (MRVI) to Release Quarterly Earnings on Wednesday
Maravai LifeSciences (NASDAQ: MRVI - Get Free Report) will likely be issuing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $49.0610 million for the quarter. Parties can find conference call details on the company's upcoming Q4 2025 earning
businesswire.com
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-984.
defenseworld.net
Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) was the target of some unusual options trading on Wednesday. Traders acquired 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average volume of 53 put options. Insider Buying and Selling at Maravai LifeSciences In related news, CEO Bernd
defenseworld.net
General American Investors Co. Inc. Takes Position in Maravai LifeSciences Holdings, Inc. $MRVI
General American Investors Co. Inc. acquired a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 136,409 shares of the company's stock, valued at approximately $391,000. General American Investors
defenseworld.net
Maravai LifeSciences (NASDAQ:MRVI) & Capricor Therapeutics (NASDAQ:CAPR) Critical Review
Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Maravai LifeSciences (NASDAQ: MRVI - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Profitability This table compares Capricor Therapeutics and
defenseworld.net
Investors Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) was the target of unusually large options trading on Wednesday. Stock traders bought 1,002 put options on the stock. This represents an increase of approximately 1,791% compared to the typical daily volume of 53 put options. Wall Street Analysts Forecast Growth Several analysts recently commented on
defenseworld.net
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Up After Insider Buying Activity
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report)'s share price gapped up before the market opened on Friday after an insider bought additional shares in the company. The stock had previously closed at $3.25, but opened at $3.45. Maravai LifeSciences shares last traded at $3.5350, with a volume of 661,436 shares traded. Specifically, CEO
businesswire.com
Maravai LifeSciences Announces November 2025 Investor Conference Schedule
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of November. On November 12, 2025, at 10:00 a.m. EST, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York City, NY. On November 19, 2025, at 10:00 a.m. GMT, Raj Asarpota, Chief Fin.
seekingalpha.com
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2025 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. ( MRVI ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Debra Hart - Senior Director of Investor Relations Bernd Brust - CEO & Director Rajesh Asarpota - EVP & Chief Financial Officer Chanfeng Zhao - Senior VP & Chief Scientific Officer Conference Call Participants Justin Bowers - Deutsche Bank AG, Research Division Madeline Mollman - Wolfe Research, LLC Thomas Peterson - Robert W. Baird & Co. Incorporated, Research Division Nathan Bolanos - UBS Investment Bank, Research Division Matthew Stanton - Jefferies LLC, Research Division Presentation Operator Good afternoon, everyone.
zacks.com
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Misses Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.02 per share a year ago.
businesswire.com
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates. Quarterly Results: Revenue of $41.6 million, Net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million “We exited the third quarter confident about the future of our business. Cygnus co.
globenewswire.com
MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders
Allegedly, Maravai misstated revenue and overstated goodwill due to weak internal controls, causing a 22% stock drop after delaying its earnings report.
businesswire.com
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 6, 2025
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2025 financial and operating results after the market close on Thursday, November 6, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 579-2543 or (785) 424-1789 and reference M.
globenewswire.com
MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What's Happening: Bragar Eagel & Squire, P.C.
globenewswire.com
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, Sept.
seekingalpha.com
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2025 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Company Participants Bernd Brust - CEO & Director Debra Hart - Senior Director of Investor Relations Rajesh J. Asarpota - EVP & Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Catherine Walden Ramsey Schulte - Robert W.